

## **PART #1 UNDERSTANDING AND PRIORITISING GAPS IN PATIENT ENGAGEMENT PRACTICES AND PROCESSES**

### **Objectives of session:**

Participants will bring their collective expertise to influence and inform the co-prioritisation and refinement of identified gaps in practices and processes of patient engagement. Results presented will evidence identified gaps in PE from a large gap analysis of existing practices and processes. Refining a potentially large number of identified gaps in practices and processes through small working groups, working interactively in real-time in this action (Part 1, Day 1, session 3) will help to inform which gaps are the most timely and important to integrate into the co-creation of the next generation of patient engagement tools by work package 4 (Part 2, Day 2 session 7). By the end of the session, participants will have co-prioritised and refined a number of gaps and collaboratively informed the direction for future co-creation of the next generation of patient engagement tools.

### **Detailed description:**

The results from a current gap analysis will likely return a greater number of contextual gaps in current practices and process that are practical or feasible to address at once. The purpose of this session is to enable patient representatives, industry, academia, regulators and other stakeholders to work together to further refine and prioritise current gaps in PE practices and process that are both practical and feasible to be incorporated into the development of a new set of patient engagement tools that can address some of those gaps.


Their input will ensure appropriateness, and importance of the eventual selected gaps in key contextual themes of; stakeholder representation, process structure, process management, and learning and changes, along with their application to the three decision making points in medicines R&D. Ye

It is encouraged that participants attend both day 1 and day 2 sessions for work package 2 and 4 to maximise value and continuity of consensus.

Participants will learn about a digital gap tool recently developed by Work Package 2 that has enabled an objective and detailed assessment of a large number of initiatives, and the results of the corresponding analysis. They will also have an opportunity to meet and learn from the PARADIGM partners and other patients and stakeholders experienced in patient engagement and the creation of tools to support its role in medicines development.

This session will begin with a brief (30 minutes) presentation of the results of work to date from work package 2 of PARADIGM, based on previously presented research undertaken in work package 1 and the key linkages with work package 4.

The second part of the session will consist of smaller group work, each group allocated a facilitator and tasked with prioritising and refining a list of identified gaps that are deemed most important, relevant and practical to be addressed through the co-creation of new toolbox. Utilising real-time voting groups will be able to vote, discuss, and critically assess their collective responses before final agreement on the



outcomes. This will be followed by discussion and feedback in the larger group. It will act as a consultation on appropriate inclusions and exclusions to be taken forward into work package 4 (Part 2, Day 2 session 7).